Open AccessTH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib
Author(s) -
Dandan Wu,
Xuexian O. Yang
Publication year - 2020
Publication title -
journal of microbiology immunology and infection
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.223
H-Index - 57
eISSN - 1995-9133
pISSN - 1684-1182
DOI - 10.1016/j.jmii.2020.03.005
Subject(s) - cytokine storm , covid-19 , medicine , pandemic , disease , immune system , immunology , virology , infectious disease (medical specialty) , outbreak
COVID-19 emerges as a pandemic disease with high mortality. Development of effective prevention and treatment is an urgent need. We reviewed TH17 responses in patients with SARS-CoV-2 and proposed an FDA approved JAK2 inhibitor Fedratinib for reducing mortality of patients with TH17 type immune profiles.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom